Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Emulate›
Products & Services
AddedJul 22, 2026
UpdatedJul 22, 2026
Brain-Chip R1

Emulate› offers Brain-Chip R1

Product
Currently Offered

iPSC-derived Organ-Chip model of the human neurovascular unit for neurological drug development.

Loading
Overview

The Brain-Chip R1 is Emulate's first-in-class isogenic Organ-Chip model of the human neurovascular unit, integrating five iPSC-derived cell types to study blood-brain barrier drug transport and neuroinflammation. It was launched in partnership with FUJIFILM Cellular Dynamics, which supplies the iPSC-derived cells.

The Brain-Chip R1 is sold as a BioKit containing Chip-R1 consumables, Brain-Chip media, and pre-qualified cells, and is compatible with the Zoë-CM2 Culture Module. It targets pharmaceutical researchers developing central nervous system therapies.

Brain-Chip R1 - Classification

Revenue
  • Transactional
Customer
  • Enterprise
Tags
  • Biotech

More from Emulate

  • AVA Emulation System logo

    AVA Emulation System

  • Zoë-CM2 Culture Module logo

    Zoë-CM2 Culture Module

  • Emulate Organ-Chip Platform logo

    Emulate Organ-Chip Platform

Brain-Chip R1 - Direct Competitors

  • MIMETAS

    MIMETAS logo

    OrganoPlate

    mimetas.com

AttributeBrain-Chip R1OrganoPlate
ProviderEmulateemulatebio.com$224.3M raisedMIMETASmimetas.com$25.7M raised · Series B
Founded20132013
Sells ToEnterprise, GovernmentPharmaceutical Manufacturers
Pricing ModelRecurring, Software, TransactionalProduct Sales, Service Fees
OwnershipPrivate, Venture CapitalPrivately Held
Brain-Chip R1

Provider Emulateemulatebio.com$224.3M raised

Founded 2013

Sells To Enterprise, Government

Pricing Model Recurring, Software, Transactional

Ownership Private, Venture Capital

OrganoPlate

Provider MIMETASmimetas.com$25.7M raised · Series B

Founded 2013

Sells To Pharmaceutical Manufacturers

Pricing Model Product Sales, Service Fees

Ownership Privately Held